Annals of Oncology

in this issue
pp. 405-405(1)

clairvoyance or reliable prediction of the future?
pp. 407-408(2)
Authors: van Zandwijk, N; van de Vijver, MJ

Chemotherapy for advanced, recurrent or metastatic endometrial cancer: a systematic review of Cochrane collaboration
pp. 409-420(12)
Authors: Humber, CE; Tierney, JF; Symonds, RP; Collingwood, M; Kirwan, J; Williams, C; Green, JA

Targeting receptor tyrosine kinases and their signal transduction routes in head and neck cancer
pp. 421-430(10)
Authors: Cruz, JJ; Ocaña, A; Del Barco, E; Pandiella, A

Occupational exposures to polycyclic aromatic hydrocarbons, and respiratory and urinary tract cancers: a quantitative review to 2005
pp. 431-446(16)
Authors: Bosetti, C; Boffetta, P; La Vecchia, C

Epidermal growth factor receptor gene copy number and protein level are not associated with outcome of non-small-cell lung cancer patients treated with chemotherapy
pp. 447-452(6)
Authors: Dziadziuszko, R; Holm, B; Skov, BG; Osterlind, K; Sellers, MV; Franklin, WA; Bunn, PA; Varella-Garcia, M; Hirsch, FR

The impact of induction chemotherapy on the outcome of second-line therapy with pemetrexed or docetaxel in patients with advanced non-small-cell lung cancer
pp. 453-460(8)
Authors: Weiss, GJ; Rosell, R; Fossella, F; Perry, M; Stahel, R; Barata, F; Nguyen, B; Paul, S; McAndrews, P; Hanna, N; Kelly, K; Bunn, PA

Randomized phase II three-arm trial with three platinum-based doublets in metastatic non-small-cell lung cancer. An Italian Trials in Medical Oncology study
pp. 461-467(7)
Authors: Bidoli, P; Zilembo, N; Cortinovis, D; Mariani, L; Isa, L; Aitini, E; Cullurà, D; Pari, F; Nova, P; Mancin, M; Formisano, B; Bajetta, E

When can a second conservative approach be considered for ipsilateral breast tumour recurrence?
pp. 468-472(5)
Authors: Gentilini, O; Botteri, E; Rotmensz, N; Santillo, B; Peradze, N; Saihum, RC; Intra, M; Luini, A; Galimberti, V; Goldhirsch, A; Veronesi, U

A comparative study on the value of FDG-PET and sentinel node biopsy to identify occult axillary metastases
pp. 473-478(6)
Authors: Veronesi, U; De Cicco, C; Galimberti, VE; Fernandez, JR; Rotmensz, N; Viale, G; Spano, G; Luini, A; Intra, M; Veronesi, P; Berrettini, A; Paganelli, G

Breast cancer patients' expectations in respect of the physician-patient relationship and treatment management results of a survey of 617 patients
pp. 479-484(6)
Authors: Oskay-Özcelik, G; Lehmacher, W; Könsgen, D; Christ, H; Kaufmann, M; Lichtenegger, W; Bamberg, M; Wallwiener, D; Overkamp, F; Diedrich, K; von Minckwitz, G; Höffken, K; Seeber, S; Mirz, R; Sehouli, J

Overexpression of ephrinB2 and EphB4 in tumor advancement of uterine endometrial cancers
pp. 485-490(6)
Authors: Alam, SM; Fujimoto, J; Jahan, I; Sato, E; Tamaya, T

RASSF1A methylation and K-ras and B-raf mutations and recurrent endometrial cancer
pp. 491-497(7)
Authors: Pijnenborg, JMA; Dam-de Veen, GC; Kisters, N; Delvoux, B; van Engeland, M; Herman, JG; Groothuis, PG

FOLFIRI.3, a new regimen combining 5-fluorouracil, folinic acid and irinotecan, for advanced pancreatic cancer: results of an Association des Gastro-Entérologues Oncologues (Gastroenterologist Oncologist Association) multicenter phase II study
pp. 498-503(6)
Authors: Taïeb, J; Lecomte, T; Aparicio, T; Asnacios, A; Mansourbakht, T; Artru, P; Fallik, D; Spano, JP; Landi, B; Lledo, G; Desrame, J

Prognostic value of expression of ERCC1, thymidylate synthase, and glutathione S-transferase P1 for 5-fluorouracil/oxaliplatin chemotherapy in advanced gastric cancer
pp. 504-509(6)
Authors: Kwon, H-C; Roh, MS; Oh, SY; Kim, S-H; Kim, MC; Kim, J-S; Kim, H-J

Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study)
pp. 510-517(8)
Authors: Pinto, C; Di Fabio, F; Siena, S; Cascinu, S; Rojas Llimpe, FL; Ceccarelli, C; Mutri, V; Giannetta, L; Giaquinta, S; Funaioli, C; Berardi, R; Longobardi, C; Piana, E; Martoni, AA

High detection rate of circulating tumor cells in blood of patients with prostate cancer using telomerase activity
pp. 518-521(4)
Authors: Fizazi, K; Morat, L; Prapotnich, D; De Crevoisier, R; Escudier, B; Cathelineau, X; Rozet, F; Vallancien, G; Sabatier, L; Soria, JC

Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy
pp. 522-528(7)
Authors: Bellmunt, J; Paz-Ares, L; Cuello, M; Cecere, FL; Albiol, S; Guillem, V; Gallardo, E; Carles, J; Mendez, P; de la Cruz, JJ; Taron, M; Rosell, R; On behalf of Spanish Oncology Genitourinary Group SOGUG,

Cost-effectiveness of postremission intensive therapy in patients with acute leukemia
pp. 529-534(6)
Authors: Yu, Y-B; Gau, J-P; You, J-Y; Chern, H-H; Chau, W-K; Tzeng, C-H; Ho, C-H; Hsu, H-C

Primary therapy for adults with T-cell lymphoblastic lymphoma with hematopoietic stem-cell transplantation results in favorable outcomes
pp. 535-540(6)
Authors: Song, KW; Barnett, MJ; Gascoyne, RD; Chhanabhai, M; Forrest, DL; Hogge, DE; Lavoie, JC; Nantel, SH; Nevill, TJ; Shepherd, JD; Smith, CA; Sutherland, HJ; Toze, CL; Voss, NJ; Connors, JM

The role of intrathecal chemotherapy prophylaxis in patients with diffuse large B-cell lymphoma
pp. 541-545(5)
Authors: Arkenau, H-T; Chong, G; Cunningham, D; Watkins, D; Agarwal, R; Sirohi, B; Trumper, M; Norman, A; Wotherspoon, A; Horwich, A

Treatment of anthracycline extravasation with Savene (dexrazoxane): results from two prospective clinical multicentre studies
pp. 546-550(5)
Authors: Mouridsen, HT; Langer, SW; Buter, J; Eidtmann, H; Rosti, G; de Wit, M; Knoblauch, P; Rasmussen, A; Dahlstrøm, K; Jensen, PB; Giaccone, G

Thrombosis-related complications and mortality in cancer patients with central venous devices: an observational study on the effect of antithrombotic prophylaxis
pp. 551-555(5)
Authors: Fagnani, D; Franchi, R; Porta, C; Pugliese, P; Borgonovo, K; Bertolini, A; Duro, M; Ardizzoia, A; Filipazzi, V; Isa, L; Vergani, C; Milani, M; On behalf of POLONORD Group,

Assessment of renal toxicity and osteonecrosis of the jaws in patients receiving zoledronic acid for bone metastasis
pp. 556-560(5)
Authors: Aguiar Bujanda, D; Bohn Sarmiento, U; Cabrera Suárez, MÁ; Aguiar Morales, J

Concerted escalation of dose and dosing duration in a phase I study of the oral camptothecin gimatecan (ST1481) in patients with advanced solid tumors
pp. 561-568(8)
Authors: Sessa, C; Cresta, S; Cerny, T; Baselga, J; Rota Caremoli, E; Malossi, A; Hess, D; Trigo, J; Zucchetti, M; D'Incalci, M; Zaniboni, A; Capri, G; Gatti, B; Carminati, P; Zanna, C; Marsoni, S; Gianni, L

A multicentre phase I and pharmacokinetic study of BN80915 (diflomotecan) administered daily as a 20-min intravenous infusion for 5 days every 3 weeks to patients with advanced solid tumours
pp. 569-575(7)
Authors: Scott, L; Soepenberg, O; Verweij, J; de Jonge, MJA; Th Planting, AS; McGovern, D; Principe, P; Obach, R; Twelves, C

A phase I trial of fixed dose rate gemcitabine plus capecitabine in metastatic cancer patients
pp. 576-580(5)
Authors: Santini, D; Virzí, V; Vincenzi, B; Rocci, L; Leoni, V; Tonini, G

Estimates of the cancer incidence and mortality in Europe in 2006
pp. 581-592(12)
Authors: Ferlay, J; Autier, P; Boniol, M; Heanue, M; Colombet, M; Boyle, P

Continuing declines in cancer mortality in the European Union
pp. 593-595(3)
Authors: Levi, F; Lucchini, F; Negri, E; La Vecchia, C

History of treated hypertension and diabetes mellitus and risk of renal cell cancer
pp. 596-600(5)
Authors: Zucchetto, A; Dal Maso, L; Tavani, A; Montella, M; Ramazzotti, V; Talamini, R; Canzonieri, V; Garbeglio, A; Negri, E; Franceschi, S; La Vecchia, C

Previously irradiated areas spared from skin toxicity induced by cetuximab in six patients: implications for the administration of EGFR inhibitors in previously irradiated patients
pp. 601-602(2)
Authors: Bossi, P; Liberatoscioli, C; Bergamini, C; Locati, LD; Fava, S; Rinaldi, G; Orlandi, E; Olmi, P; Tagliabue, E; Ménard, S; Licitra, L

Thymoma and progressive T-cell lymphocytosis
pp. 603-604(2)
Authors: Morales, M; Trujillo, M; del Carmen Maeso, M; Piris, M-A

Artificial intelligences in urological practice: the key to success?
pp. 604-605(2)
Authors: Cai, T; Conti, G; Lorenzini, M; Bartoletti, R

Metastin (KISS-1) and metastin-coupled receptor (GPR54) expression in transitional cell carcinoma of the bladder
pp. 605-607(3)
Authors: Nicolle, G; Comperat, E; Nicolaïew, N; Cancel-Tassin, G; Cussenot, O

Lethal toxicity of uracil/tegafur in the treatment of sigmoid carcinoma
pp. 607-608(2)
Authors: Bosch, TM; Meijerman, I; Beijnen, JH; van Thiel, SW; Vlasveld, LT

Are sales representatives and the sale strategies of pharmaceutical companies getting too aggressive towards physicians?
pp. 607-607(1)
Authors: Bernardi, D; Errante, D; Bianco, A; Salvagno, L

Reversible posterior leukoencephalopathy syndrome after carboplatin therapy
pp. 608-609(2)
Authors: Vieillot, S; Pouessel, D; de Champfleur, NM; Becht, C; Culine, S

Does low-molecular-weight heparin influence cancer-related mortality?
pp. 609-610(2)
Author: Meyer, G

Celecoxib reduces microvessel density in patients treated with nasopharyngeal carcinoma and induces changes in gene expression. Ann Oncol 2006; 17: 1625-1630
pp. 611-611(1)
Authors: Soo, RA; Wu, J; Aggarwal, A; Tao, Q; Hsieh, W; Putti, T; Tan, KB; Soon, WL; Lai, YF; Mow, B; Hsu, S; Loh, KS; Tan, L; Tan, P; Goh, B-C